One partner. Fully connected. A flexible approach to biologics—BIO 2025, booth #2953

How Syngene delivered pre-IND to IND Safety studies for a leading biotech company in just three months

syngene-delivered

Learn how Syngene partnered with a biotech company to deliver pre-IND to IND Safety studies in just three months for a treatment therapy for gut-brain diseases.

Author

Latest Blogs

Harnessing the power of induced proximity-based drugs and precision medicine for treating cancer

PROTAC-blog

Five questions that determine the success of your PROTAC programs

Solving-problems-with-science

Solving problems with science: Gene to GMP-grade clinical supply in nine months

Blog-Sustainability-at-Syngene

Minimizing environmental footprint the Syngene way

Driving operational excellence with SQDECC

How Organocatalysis discovered by Nobel laureates revolutionised drug development and production in Syngene

To view or email, Please share your details view

To download, Please share your details

To download, Please share your details